Job title: Director, Research & Business Development
Dr. Briand has served as an expert in metabolic diseases since October 2007. In collaboration with the industry, he has worked extensively on the development of novel in vivo assays and animal models of obesity/type 2 diabetes and related co-morbidities, all presented in international meetings and published in numerous publications. Dr. Briand received the ASBMB Journal of Lipid Research Junior Investigator Award in 2016, as well as the Berman-Zech Award in 2018, for his research work on preclinical evaluation of drugs targeting type 2 diabetes, dyslipidemia, diabetic nephropathy and NASH. In 2006, he worked in the laboratory of Pr. Daniel J Rader in Philadelphia, USA. In collaboration with pharmaceutical companies, his work focused on novel drugs affecting lipoprotein metabolism and reverse cholesterol transport in various mouse models, in collaboration with Glaxo Smith Kline. In 2006, Dr. Briand earned his Ph.D in Nutrition and Metabolism from the University of Nantes, France. It dealt with the development of a canine model of obesity and insulin resistance, for evaluating drugs targeting type 2 diabetes and diabetic dyslipidemia, in collaboration with Novo Nordisk.